GlassScriptPhysician profile
Emily Beth Kendall
NPI 1396923322
$5,273.07
in general payments reported to CMS, 2019-2025
23 companies · $2,683 in 2025
The $2,683 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $348 · 2024: $2,242 · 2025: $2,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,998 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,998.08 |
| Education | $274.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,643.34 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $626.68 | 2023-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $509.31 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $496.27 | 2023-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $271.41 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $259.13 | 2024-2025 | Omvoh |
| Genzyme Corporation | $244.58 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $195.43 | 2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $147.97 | 2025 | Entyvio |
| Madrigal Pharmaceuticals | $124.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $113.37 | 2024 | |
| Vivus LLC | $107.17 | 2024-2025 | Pancreaze |
| Evoke Pharma, INC. | $97.40 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $94.00 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $82.95 | 2024-2025 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $54.23 | 2024-2025 | |
| Celgene Corporation | $51.14 | 2023-2024 | Zeposia |
| Celltrion USA INC. | $33.34 | 2024-2025 | Vegzelma |
| Novo Nordisk INC | $33.27 | 2025 | Wegovy |
| Organon LLC | $26.37 | 2023-2025 | Hadlima |
| Intercept Pharmaceuticals, INC. | $21.99 | 2023 | Ocaliva |
| Daiichi Sankyo INC. | $19.80 | 2024 | Injectafer |
| Gilead Sciences, INC. | $19.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Kendall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.